WHO’s Guidance of Ethics and Governance AI Usage

By Sumona Bose

January 30, 2024

Introduction

The World Health Organization (WHO) has released new guidance on the ethics and governance of large multi-modal models (LMMs), which are generative AI technologies that have the potential to improve healthcare outcomes. The guidance includes over 40 recommendations for governments, technology companies, and healthcare providers to ensure the appropriate use of LMMs. LMMs are unique in their ability to accept various types of data inputs, such as text, videos, and images, and generate diverse outputs. They mimic human communication and can perform tasks that they were not explicitly programmed to do. These technologies have been adopted at an unprecedented rate, with platforms like ChatGPT, Bard, and Bert gaining popularity in 2023. This article will discuss WHO’s Guidance of Ethics and Governance AI Usage.

Guiding AI’s Role in Healthcare

The potential benefits of LMMs in healthcare are vast. They can be used for diagnosis and clinical care, patient-guided use, clerical and administrative tasks, medical and nursing education, and scientific research and drug development. However, there are also risks associated with the use of LMMs. They can produce false, inaccurate, biased, or incomplete statements. These could harm individuals relying on this information for their health decisions. LMMs may also be trained on poor quality or biased data, leading to potential disparities in healthcare outcomes.

WHO - Ethics And Governance of Artificial Intelligence - DigitalRosh
Figure 1: WHO Guidance on Ethics and Governance on AI for Health

The guidance also highlights broader risks to health systems, such as the accessibility and affordability of the best-performing LMMs. There is a concern that healthcare professionals and patients may develop “automation bias,” relying too heavily on LMMs and overlooking errors or improperly delegating difficult choices to these technologies. Additionally, LMMs are vulnerable to cybersecurity risks, which could compromise patient information and the trustworthiness of these algorithms.

Ensuring a multi-stakeholder framework of AI

To ensure the safe and effective use of LMMs, the WHO emphasizes the need for engagement from various stakeholders, including governments, technology companies, healthcare providers, patients, and civil society. Governments have a primary responsibility to set standards for the development and deployment of LMMs, including their oversight and regulation. The guidance recommends that governments invest in public infrastructure and provide access to computing power and public data sets while adhering to ethical principles and values. WHO’s Guidance of Ethics and Governance AI Usage can be considered as an important framework of universal applicability.

Conclusion

Developers of LMMs should involve potential users and stakeholders, including medical providers, researchers, healthcare professionals, and patients, in the design process. LMMs should be designed to perform well-defined tasks with accuracy and reliability, improving the capacity of health systems.

Reference url

Recent Posts

athlete risk stratification
Advancing Athlete Risk Stratification with Predictive Frameworks

By João L. Carapinha

June 11, 2026

Athlete risk stratification now integrates epidemiological evidence, explainable artificial intelligence, and mechanistic cardiac models to better protect young competitors. This convergence offers a path to distinguish healthy athletic remodeling from hidden substrates that can trigger fatal arr...
Innovative Therapies Access Portugal
Evaluating Innovative Therapies Access in Portugal

By João L. Carapinha

June 11, 2026

According to Paulo Gonçalves in the APIFARMA newsletter, Innovative Therapies Access in Portugal directs resources toward therapeutic innovation at levels substantially below feasible ambitions. Protracted authorization processes impose measurab...
Dutch Medicine Access Delay
Dutch Medicine Access Delay Impact on Patient Care in the Netherlands

By João L. Carapinha

June 10, 2026

Dutch Medicine Access Delay leaves patients in the Netherlands waiting far longer for innovative drugs than those in Germany. Of 51 treatments currently held in the Dutch assessment pathway, 48 are already on the market across the border, revealing a persistent structural lag driven by mandatory ...